Matthew D. Galsky, MD

Articles

Managing Toxicities in Short- and Long-Term Treatment with ADCs

August 8th 2024

Vijayakrishna Gadi, MD, PhD, discusses short-term and long-term treatments with ADCs.

Managing ILD and Pneumonitis Risk From ADCs

August 8th 2024

Vijayakrishna Gadi, MD, PhD, discusses the risk of ILD and pneumonitis from ADCs.

The Potential Role for HER2-Targeted ADCs in Earlier Treatment Lines

August 1st 2024

Vijayakrishna Gadi, MD, PhD, discusses the role of antibody-drug conjugates in a curative setting.

Overcoming Challenges of Testing for HER2-low Across Solid Tumor Types

August 1st 2024

A panel of experts discuss the challenges of testing for HER2-low access solid tumor types.

ADCs Targeting HER2+ GU Cancers

July 23rd 2024

A panel of experts discuss if there is a role for HER2-directed ADCs antibody-drug conjugates in GU genitourinary cancers

Impact of ADCs on Brain Metastases

July 23rd 2024

A panel of experts discuss where HER2-directed ADCs antibody-drug conjugates fit into the overall treatment paradigm.

ADCs Targeting HER2+ Lung Cancer

July 12th 2024

Dr Garon shares insights on the role of ADCs for the treatment of HER2+ lung cancer.

Emerging Data from ASCO 2024 in HER2-low: DESTINY-Breast06

July 12th 2024

Dr Gadi leads a discussion on recent data on the treatment of HER2-low tumors, including ASCO updates on the DESTINY-Breast06 trial.

ADCs Targeting GI Cancers

July 12th 2024

Dr Parikh discusses the history of ADCs for treating GI cancers with a focus on the data for T-DXd and its role in treating these cancers.

ADCs Targeting HER2+ Gynecologic Cancers

July 12th 2024

Dr Campos discusses the potential for T-DXd in other gynecologic cancers and offers an overview of results from the DESTINY-PanTumor02 trial.

ADCs Targeting HER2+ Breast Cancer

June 25th 2024

Dr Gadi introduces treatment and trial data targeting care for patients diagnosed with HER2+ breast cancer.

Assessing HER2 Status Across Tumor Types

June 25th 2024

Dr Gadi leads a discussion surrounding HER2 mutation and overexpression across various cancer types.

Dr Galsky on the FDA Approval of Nivolumab Plus Chemotherapy in Urothelial Carcinoma

March 29th 2024

Matthew Galsky, MD, discusses the significance of the FDA approval of frontline nivolumab plus chemotherapy patients with metastatic urothelial carcinoma.

Extended Follow-up Results From CheckMate 274: Adjuvant Nivolumab in MIUC

March 10th 2023

Expert Matthew D. Galsky, MD, shares his perspective on follow-up results from CheckMate 274, which analyzed adjuvant nivolumab in patients with high-risk muscle-invasive urothelial carcinoma.

Dr. Galsky on Updated Findings From the CheckMate-274 Trial in Urothelial Cancer

February 17th 2023

Matthew Galsky, MD, discusses the key findings from extended follow-up of the phase 3 CheckMate-274 trial in urothelial cancer.

Dr. Galsky on Clinical Trials That Addressed Key Questions in Urothelial Cancer

January 24th 2022

Matthew Galsky, MD, discusses clinical trials that addressed key questions in urothelial cancer.

Dr. Galsky on Sequencing Questions in Urothelial Cancer

June 23rd 2020

Matthew Galsky, MD, discusses sequencing questions in urothelial carcinoma.

Dr. Galsky on the HCRN GU14-182 Study Results in Urothelial Cancer

August 6th 2019

Matthew D. Galsky, MD, director, Genitourinary Medical Oncology, The Tisch Cancer Institute, Mount Sinai Hospital, discusses results from the HCRN GU14-182 study, which examined maintenance pembrolizumab versus placebo in patients with metastatic urothelial cancer.

Checkpoint Inhibitors Herald a New Era for Treating Urothelial Cancer

November 7th 2017

Decades of clinical trials exploring modifications of cytotoxic regimens, including the use of different or more drugs, demonstrated that a therapeutic plateau had been reached with conventional chemotherapeutic agents, highlighting the need for novel approaches in urothelial carcinoma.

Atezolizumab Shows Promise of PD-1/PD-L1 Blockade in Metastatic Bladder Cancer

November 4th 2015

Immune checkpoint blockade has transformed the treatment paradigms of multiple advanced solid tumors-and bladder cancer is no exception.